Sou Hu Cai Jing·2026-01-29 10:23Core Viewpoint - The company, Tigermed, forecasts a net profit of RMB 330 million to RMB 490 million for the year 2025, excluding non-recurring gains and losses, indicating a significant recovery in its financial performance compared to the previous year [1]. Financial Performance - The non-recurring gains and losses attributable to shareholders are expected to be between RMB 500 million and RMB 740 million, a substantial increase from the previous year's loss of RMB 449.75 million, resulting in a net increase of RMB 949.75 million to RMB 1.18975 billion [2]. - The company's operating revenue is projected to be between RMB 6.66 billion and RMB 7.68 billion, reflecting a year-on-year increase of 1% to 16%, marking a return to growth [3]. - The net cash flow from operating activities is estimated to be between RMB 1.1 billion and RMB 1.3 billion, showing a slight increase from RMB 1.097 billion in the previous year [4]. Order Growth and Market Position - The company anticipates new net orders in the range of RMB 9.5 billion to RMB 10.5 billion for 2025, compared to RMB 8.42 billion in 2024, indicating strong growth in order intake [3]. - Tigermed maintains its leading position in the Chinese clinical research outsourcing (CRO) industry, with its market share ranked first according to Frost & Sullivan [3]. Profitability and Challenges - The net profit attributable to shareholders, excluding non-recurring gains and losses, is expected to be between RMB 330 million and RMB 490 million, a decrease of 43% to 61% compared to the previous year's profit of RMB 854.9 million [5]. - Factors contributing to the decline in profit include cancellations of historical orders and increased operational costs due to team expansions in response to industry demand recovery [5]. - The average price of new orders has stabilized after a decline in recent years, which had previously impacted profit margins [5]. Recent Quarterly Performance - For the first three quarters of 2025, the company's main revenue was RMB 5.026 billion, a slight decrease of 0.82% year-on-year, while the net profit attributable to shareholders was RMB 1.02 billion, an increase of 25.45% [6]. - The third quarter alone saw main revenue of RMB 1.775 billion, a year-on-year increase of 3.86%, with a net profit of RMB 637 million, up 98.73% year-on-year [6].